Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

Martínez‐López, Joaquín; Mateos, María Victoria; Encinas, Cristina; Sureda, Anna; Hernández‐Rivas, José Ángel; Guía, Ana López de la; Conde, Diego; Krsnik, Isabel; Prieto, Elena; Grau, Rosalía Riaza; Gironella, Mercedes; Blanchard, María Jesús; Caminos, Nerea; Larrea, Carlos Fernández de; Senin, María Alicia; Escalante, Fernando; Puerta, José Enrique de la; Gimenez, Eugenio; Martínez-Barranco, Pilar; Mateos, Juan José Nava; Casado, Luis Felipe; Bladé, Joan; Lahuerta, Juan José; Cruz, Javier de la; Miguel, Jesús F. San

doi:10.1038/s41408-020-00372-5

Cited by 67 publications

(69 citation statements)

References 27 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ongoing COVID-19 pandemic has even shed a light on the importance of comorbidities, where up to 75% MM patients who got infected by the virus and admitted to hospital had a comorbidity at diagnosis, and over 80% of patients who died from COVID suffered from other diseases than MM. 35 In the current study, 14 diseases were related to a higher risk of death. Patients with dementia had the highest risk of death (72% higher), followed by heart failure which increased the risk by 54%.…”

Section: Discussionmentioning

confidence: 49%

Comorbidities in multiple myeloma and implications on survival: A population‐based study

Sverrisdottir

Rögnvaldsson

Þorsteinsdóttir

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

High proportion of patients with multiple myeloma suffer from comorbidities which may alter clinical management. Therefore, our aims were to evaluate the prevalence of comorbidities and their impact on survival. We included patients diagnosed with multiple myeloma 1990‐2013 in Sweden and all diagnoses from each patient from 1985. A total of 13 656 patients with multiple myeloma were included in the study, thereof 7404 (54%) had comorbidity at diagnosis. The risk of death was increased for those with one comorbidity at diagnosis compared to those without any comorbidity (hazard ratio = 1.19; 95% confidence interval:1.14‐1.25); this risk was higher for those with two (1.38; 1.30‐1.47) and three or more comorbidities (1.72; 1.62‐1.83). Furthermore, the risk of death was increased in patients with prior history of cancer, arrhythmia, heart failure, diabetes mellitus, cerebrovascular disease, chronic lung disease, psychological disease, peptic ulcer, neurological disease, peripheral vascular disease, chronic kidney disease, dementia, and inflammatory bowel disease. This large study shows that over 50% of multiple myeloma patients have a comorbidity at diagnosis and survival decreased with increasing numbers of comorbidities. This emphasizes the importance of comorbidities when evaluating patients and deciding on treatment strategies for individuals with multiple myeloma.

show abstract

Section: Discussionmentioning

confidence: 49%

Comorbidities in multiple myeloma and implications on survival: A population‐based study

Sverrisdottir

Rögnvaldsson

Þorsteinsdóttir

et al. 2021

European J of Haematology

View full text Add to dashboard Cite

show abstract

“…A recent study from Spain found a higher mortality rate in MM patients with COVID-19 (34%) compared with age- and sex-matched non-MM patients with COVID-19 (23%). 21 A recent publication from France confirmed overall mortality in all hospitalized patients with COVID-19 to be 16%, which is significantly lower than mortality observed in hospitalized MM patients in France (39%). 22 Our data clearly suggest a lack of relationship between prior lines of therapy or prior type of therapy, or those receiving active MM therapy at the time of diagnosis with COVID-19 and outcome.…”

Section: Discussionmentioning

confidence: 93%

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Chari

Samur

Martínez‐López

et al. 2020

Blood

Self Cite

163

162

View full text Add to dashboard Cite

The primary cause of morbidity and mortality in patients with multiple myeloma(MM) is an infection. Therefore there is great concern about the susceptibility to the outcome of COVID-19 infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during COVID-19 pandemic. Analysis were performed for hospitalized MM patients. Among hospitalized patinets, the median age was 69 years, and nearly all patients(96%) had MM. Approximately 36% were recently diagnosed(2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, ISS3, high-risk disease, renal disease, suboptimal myeloma control(active or progressive disease), and one or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.

show abstract

“…Moreover, they were demonstrated that uncontrolled MM and renal insufficiency were independent factor of death in hospitalized patients with COVID19. 9 Besides, this case presented poor prognostic factor: age >65 years, progressive disease, and renal disease.…”

Section: Discussionmentioning

confidence: 80%

Second COVID-19 infection in a patient with multiple myeloma in Brazil – reinfection or reactivation?

Bellesso

Bruniera

Trunkel

et al. 2021

Hematology, Transfusion and Cell Therapy

View full text Add to dashboard Cite

Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality

Cited by 67 publications

References 27 publications

Comorbidities in multiple myeloma and implications on survival: A population‐based study

Comorbidities in multiple myeloma and implications on survival: A population‐based study

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set

Second COVID-19 infection in a patient with multiple myeloma in Brazil – reinfection or reactivation?

Contact Info

Product

Resources

About